ProBiotix partners to distribute CholBiome cardiovascular probiotics in South Korea
The CholBiome line has been clinically shown to reduce elevated cholesterol and blood pressure levels.
ProBiotix Health, a subsidiary of microbiome-ingredients firm OptiBiotix Health (York, UK), has signed an exclusive deal to bring its CholBiome line of probiotic ingredients for cardiovascular health to the South Korean market.
ProBiotix will work with Inscobee, a public company on the Korean stock market which sells nutraceuticals through hospitals, retail stores, and e-commerce, to bring the ingredients to market. In a press release, ProBiotix notes that, “Over the past decade, there has been an increase in chronic disease in Korea, with a notable rise in cardiovascular diseases (CVDs). CVDs have become one of the leading causes of morbidity and mortality in Korea and in fact are the second most common cause of mortality in the country.”
The CholBiome line has been clinically shown to reduce elevated cholesterol and blood pressure levels. The ingredients feature the patented probiotic ingredient LPLDL, a strain of Lactobacillus plantarum. The ingredient “is a naturally occurring bacterium that harnesses the microbiome-liver axis to impact positively upon the gut microbiome,” OptiBiotix explains on its website. “Its outstanding ability to modulate bile acid metabolism is beneficial for heart health factors such as high blood pressure and high cholesterol, as well as other processes from liver function to glucose regulation and vitamin metabolism.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
